ABOS Stock Price, Acumen Pharmaceuticals, . Quote, Chart

Market Summary

USD3.72-0.01

Delayedas of 17 May 2024, 01:58 pm

-0.27%

ABOS Stock Price

View Fullscreen

ABOS RSI Chart

ABOS Valuation

Market Cap

224.1M

Price/Earnings (Trailing)

-4.01

Price/Sales (Trailing)

20.77

Price/Free Cashflow

-4.42

ABOS Price/Sales (Trailing)

ABOS Profitability

Return on Equity

-21.35%

Return on Assets

-18.59%

Free Cashflow Yield

-22.65%

ABOS Fundamentals

ABOS Revenue

Revenue (TTM)

10.8M

ABOS Earnings

Earnings (TTM)

-55.9M

Earnings Growth (Yr)

-31.54%

Earnings Growth (Qtr)

9.84%

Breaking Down ABOS Revenue

52 Week Range

3.6711.31

(Low)(High)

Last 7 days

4.8%

Last 30 days

6.9%

Last 90 days

14.0%

Trailing 12 Months

-31.4%

How does ABOS drawdown profile look like?

ABOS Financial Health

Current Ratio

30.2

Debt/Equity

0.12

Debt/Cashflow

-1.68

ABOS Investor Care

Shares Dilution (1Y)

46.45%

Diluted EPS (TTM)

-1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q4
2024	0	0
2023	6.6M	10.8M
2022	0	2.4M
2020	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Acumen Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 19, 2024	oconnell daniel joseph	sold	-52,753	3.4706	-15,200	president and ceo
Jan 19, 2024	meisner derek m	sold	-31,048	3.4757	-8,933	chief legal officer & corp sec
Jan 18, 2024	barton russell	sold	-10,555	3.7258	-2,833	chief operating officer
Jan 18, 2024	siemers eric	sold	-11,603	3.7144	-3,124	chief medical officer
Jan 18, 2024	zuga matt	sold	-15,716	3.705	-4,242	cfo & chief business officer
Jan 02, 2024	meisner derek m	acquired	-	-	91,000	chief legal officer & corp sec
Jan 02, 2024	zuga matt	acquired	-	-	106,000	cfo & chief business officer
Jan 02, 2024	oconnell daniel joseph	acquired	-	-	401,000	president and ceo
Jan 02, 2024	siemers eric	acquired	-	-	94,000	chief medical officer
Jan 02, 2024	barton russell	acquired	-	-	73,000	chief operating officer

Which funds bought or sold ABOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Rock Springs Capital Management LP	unchanged	-	483,012	9,315,240	0.24%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	3,135,730	60,474,900	0.78%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	added	27.15	38,106	149,850	0.01%
May 15, 2024	Laurion Capital Management LP	unchanged	-	397,955	7,674,840	0.06%
May 15, 2024	Hudson Bay Capital Management LP	reduced	-0.78	100,704	2,268,000	0.01%
May 15, 2024	Alyeska Investment Group, L.P.	added	28.15	989,892	3,805,390	0.02%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	67.31	380,802	878,850	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-301,175	-	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	228,294	228,294	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-95.15	-105,991	5,711	-%

Are Funds Buying or Selling ABOS?

Are funds buying ABOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABOS

No. of Funds

Unveiling Acumen Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 06, 2024	franklin resources inc	5.8%	3,358,809	SC 13G
Jan 24, 2024	murray james b jr	4.6%	2,681,057	SC 13G/A
Jul 25, 2023	ra capital management, l.p.	25.9%	14,981,618	SC 13D/A
Feb 14, 2023	manning paul b	7.8%	3,205,128	SC 13G/A
Feb 14, 2023	deep track capital, lp	9.66%	3,952,000	SC 13G/A
Feb 14, 2023	sands capital ventures, llc	2.7%	1,124,729	SC 13G/A
Oct 07, 2022	blackrock inc.	2.8%	1,115,027	SC 13G/A
Feb 16, 2022	hardie molly g.	8.5%	3,451,152	SC 13G
Feb 15, 2022	manning paul b	9.9%	4,010,678	SC 13G

Recent SEC filings of Acumen Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 24, 2024	EFFECT	EFFECT
Apr 22, 2024	DEFA14A	DEFA14A
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	ARS	ARS
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 27, 2024	S-3	S-3
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report

Peers (Alternatives to Acumen Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Acumen Pharmaceuticals, Inc. News

Latest updates

Acumen Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2020Q4	2020Q3	2020Q2
Revenue	37.2%	4,005	2,919	1,832	1,465	1,097	730	151
Operating Expenses	-3.9%	17,774	18,486	13,135	14,249	-	3,220	2,186
S&GA Expenses	-100.0%	-	5,193	4,422	3,503	-	226	259
R&D Expenses	-6.3%	12,449	13,293	8,713	10,746	-	2,994	1,927
Interest Expenses	-	756	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-
Net Income	9.8%	-14,873	-16,497	-11,307	-12,866	-	-2,490	-2,035
Net Income Margin	-6.8%	-5.18*	-4.85*	-6.83*	-17.92*	-5.10*	-	-
Free Cashflow	-114.8%	-17,859	-8,314	-10,175	-11,203	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-3.0%	301	310	286	177	188	197	203	212	220	230	235	73.00	44.00
Current Assets	3.7%	256	247	219	150	144	180	203	191	192	199	205	71.00	44.00
Cash Equivalents	-29.5%	47.00	67.00	95.00	77.00	78.00	130	158	111	109	122	136	69.00	44.00
Net PPE	-4.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Liabilities	-9.8%	39.00	43.00	6.00	9.00	9.00	8.00	7.00	5.00	4.00	5.00	1.00	5.00	6.00
Current Liabilities	-34.7%	8.00	13.00	6.00	9.00	9.00	8.00	7.00	5.00	4.00	5.00	-	-	-
Long Term Debt	1.0%	30.00	30.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-1.8%	262	267	280	169	179	189	197	207	216	225	233	-	-
Retained Earnings	-6.7%	-237	-222	-206	-193	-181	-170	-157	-146	-136	-127	-119	-115	-27.00
Additional Paid-In Capital	2.1%	500	489	487	363	361	360	355	354	354	353	353	9.00	8.00
Shares Outstanding	3.7%	60.00	58.00	58.00	41.00	41.00	41.00	40.00	40.00	40.00	40.00	38.00	-	0.00
Float	-	-	-	-	134	-	-	-	135	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-114.8%	-17,859	-8,314	-12,905	-11,670	-10,175	-11,203	-9,183	-6,468	-8,299	-3,639	-7,688	-4,264	-2,370	-	-	-
Share Based Compensation	52.0%	2,484	1,634	1,600	1,521	1,390	888	840	715	618	365	304	127	126	-	-	-
Cashflow From Investing	81.1%	-9,203	-48,807	-92,001	11,064	-41,927	-20,420	55,919	8,785	-5,099	-	-	-	-	-	-	-
Cashflow From Financing	-75.6%	7,107	29,134	122,764	-145	-	4,184	-263	-	-	10.00	168,781	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABOS Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 12,449	$ 8,713
General and administrative	5,325	4,422
Total operating expenses	17,774	13,135
Loss from operations	(17,774)	(13,135)
Other income (expense)
Interest income	4,005	1,832
Interest expense	(1,000)	0
Change in fair value of embedded derivatives	(50)	0
Other expense, net	(54)	(4)
Total other income	2,901	1,828
Net loss	(14,873)	(11,307)
Other comprehensive gain (loss)
Unrealized loss on marketable securities	(456)	227
Comprehensive loss	$ (15,329)	$ (11,080)
Net loss per common share, basic (in dollars per share)	$ (0.25)	$ (0.28)
Net loss per common share, diluted (in dollars per share)	$ (0.25)	$ (0.28)
Weighted-average shares outstanding, basic (in shares)	59,812,000	41,025,062
Weighted-average shares outstanding diluted (in shares)	59,812,000	41,025,062

ABOS Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 46,930	$ 66,886
Marketable securities, short-term	205,582	176,636
Prepaid expenses and other current assets	3,319	3,093
Total current assets	255,831	246,615
Marketable securities, long-term	44,108	62,553
Right-of-use asset	353	381
Restricted cash	234	233
Property and equipment, net	117	122
Other assets	324	221
Total assets	300,967	310,125
Current liabilities
Accounts payable	3,079	1,379
Accrued clinical trial expenses	2,367	4,387
Accrued expenses and other current liabilities	2,905	6,339
Finance lease liability, short-term	0	756
Operating lease liability, short-term	121	110
Total current liabilities	8,472	12,971
Operating lease liability, long-term	252	284
Debt, long-term	30,209	29,897
Total liabilities	38,933	43,152
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	499,843	489,453
Accumulated deficit	(237,671)	(222,798)
Accumulated other comprehensive income (loss)	(144)	312
Total stockholders’ equity	262,034	266,973
Total liabilities and stockholders’ equity	$ 300,967	$ 310,125

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

CEO	Mr. Daniel J. O'Connell M.B.A.
WEBSITE	https://acumenpharm.com
INDUSTRY	Biotechnology
EMPLOYEES	39

Acumen Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Acumen Pharmaceuticals, Inc.? What does ABOS stand for in stocks?

ABOS is the stock ticker symbol of Acumen Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acumen Pharmaceuticals, Inc. (ABOS)?

As of Thu May 16 2024, market cap of Acumen Pharmaceuticals, Inc. is 224.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers. The fair value of Acumen Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acumen Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acumen Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ABOS is over valued or under valued. Whether Acumen Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acumen Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABOS.

What is Acumen Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ABOS's PE ratio (Price to Earnings) is -4.01 and Price to Sales (PS) ratio is 20.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABOS PE ratio will change depending on the future growth rate expectations of investors.